Equity Offerings
-
-
-
-
-
-
-
Summit Therapeutics partners with GSK for cancer drug combination trial
-
-
-
-
-
-
-
Ivonescimab shows survival benefit in lung cancer study
-
-
-
-
-
-
-
Summit Therapeutics plans to submit BLA for cancer drug in Q4 2025
-
-
-
-
-
-
-
Summit presents lung cancer trial data at ESMO 2025
-
-
-
-
-
-
-
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
-
-
-
-
-
-
-
Summit Therapeutics (SMMT): Interim OS Analysis Requested from Chinese Health Authorities Shows Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive A
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) appoints Robert LaCaze as CCO
-
12,645 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

